Objective:
Major depressive disorder (MDD) is related to glutamatergic dysfunction. Antagonists of glutamatergic N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have antidepressant properties. Nitrous oxide (N
2
O) is also a NMDAR antagonist. Thus, this study aimed to evaluate the effects of augmenting antidepressant treatment with N
2
O.
Methods:
This double blind, placebo-controlled randomized parallel pilot trial was conducted from June 2016 to June 2018 at the Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Twenty-three subjects with MDD (aged 18 to 65, on antidepressants, with a score > 17 on the 17-item-Hamilton Depression Rating Scale [HAM-D
17
]) received 50% N
2
O (n=12; 37.17±13.59 years) or placebo (100% oxygen) (n=11; 37.18±12.77 years) for 60 minutes twice a week for 4 weeks. The primary outcome was changes in HAM-D
17
from baseline to week 4.
Results:
Depressive symptoms improved significantly in the N
2
O group (N
2
O: from 22.58±3.83 to 5.92±4.08; placebo: from 22.44±3.54 to 12.89±5.39, p < 0.005). A total of 91.7% and 75% of the N
2
O group subjects achieved response (≥ 50% reduction in HAM-D
17
score) and remission (HAM-D
17
< 7), respectively. The predominant adverse effects of N
2
O treatment were nausea, vomiting, and headache.
Conclusion:
N
2
O treatment led to a statistically significant reduction in HAM-D
17
scores compared to placebo.
Clinical trial registration:
Brazilian Register of Clinical Trials, RBR-5rz5ch
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.